Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI343 + gemcitabine + albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBI343 + gemcitabine + albumin-bound paclitaxel is an investigational combination therapy being developed by Innovent Biologics for the treatment of advanced solid tumors, specifically claudin 18.2 (CLDN18.2)-positive gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and pancreatic ductal adenocarcinoma. IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) utilizing a topoisomerase I inhibitor payload (exatecan). It targets tumor cells expressing CLDN18.2, leading to internalization and the release of the cytotoxic payload. Gemcitabine is a nucleoside metabolic inhibitor that interferes with DNA synthesis, while albumin-bound paclitaxel (nab-paclitaxel) is a microtubule inhibitor that disrupts mitotic processes. This combination therapy aims to enhance anti-tumor efficacy by combining targeted ADC delivery with systemic chemotherapy in patients with CLDN18.2-expressing malignancies.
- Brand names
- AbraxaneGemzar
- Other names
- IBI343 in combination with gemcitabine and albumin-bound paclitaxelIBI-343 in combination with gemcitabine and albumin-bound paclitaxelIBI 343 in combination with gemcitabine and albumin-bound paclitaxelIBI343 + gemcitabine + nab-paclitaxel
02
Targets
Claudin 18.2TOP1 (DNA Topoisomerase I)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IBI343 + gemcitabine + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI343 + gemcitabine + albumin-bound paclitaxel.